Table 1.
Healthy controls | BOD patients | EOC patients | |
---|---|---|---|
Number of patients | 33 | 20 | 20 |
Age | |||
Mean | 52 | 57 | 57 |
Median | 50 | 52 | 58 |
Range | 40–81 | 35–97 | 40–78 |
SD | 10.08 | 14.36 | 10.46 |
Stage | |||
I | — | — | 10 |
II | — | — | 10 |
Grade | |||
1 | — | — | 1 |
2 | — | — | 10 |
3 | — | — | 9 |
GLYCOV value∗ | |||
Mean | 0.21 | 0.42 | 4.31 |
Median | 0.13 | 0.38 | 2.90 |
Range | 0.00–0.83 | 0.02–1.27 | 0.56–12.82 |
SD | 0.21 | 0.29 | 3.84 |
CA125 (kU/L) | |||
Mean | 14.45 | 36.90 | 225.86 |
Median | 12.00 | 30.50 | 65.50 |
Range | 6–38 | 12–100 | 6–1474 |
SD | 6.92 | 24.36 | 375.87 |
∗GLYCOV values were calculated using the relative areas obtained from the MALDI-TOF-MS spectra: (sum of relative areas of m/z 3776.8, 3950.9, 4226.1, 4400.2, 4587.4, 4761.5, 4935.7)/7∗4/ (sum of relative areas of m/z 1579.7, 1783.8, 1987.9 and 2192.0).